TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.